SCHEMBL20401627

SCHEMBL20401627

N#Cc1cccc(-c2cc(-c3cn(Cc4cc(C(=O)O)ccn4)nn3)nc(N)n2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 13/20 0.47
▸ ADORA1 P30542 3/20 0.47
▸ UCHL5 Q9Y5K5 2/20 0.44
▸ UCHL1 P09936 1/20 0.44
▸ UCHL3 P15374 1/20 0.44
▸ ADORA2B P29275 9/20 0.43
▸ KDM6B O15054 2/20 0.42
▸ KDM5C P41229 2/20 0.42
▸ KDM2A Q9Y2K7 2/20 0.42
▸ KDM3A Q9Y4C1 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.41
▸ KDM4A O75164 1/20 0.41
▸ KDM4C Q9H3R0 1/20 0.41
▸ PDE4A P27815 1/20 0.41
▸ PDE4C Q08493 1/20 0.41
▸ PDE4D Q08499 1/20 0.41
▸ CDC7 O00311 1/20 0.40
▸ DAPK3 O43293 1/20 0.40
▸ ROCK2 O75116 1/20 0.40
▸ PAK4 O96013 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20400598 0.90 ADORA2A (0.52) ADORA2AADORA1ADORA2B
SCHEMBL30402302 0.88 ADORA2A (0.46) ADORA2AADORA1UCHL5UCHL1UCHL3
SCHEMBL20401237 0.88 ADORA2A (0.46) ADORA2AADORA1UCHL5UCHL1UCHL3
SCHEMBL30400781 0.87 UCHL5 (0.55) ADORA2AADORA1UCHL5UCHL1UCHL3
SCHEMBL20400588 0.87 UCHL5 (0.55) ADORA2AADORA1UCHL5UCHL1UCHL3
SCHEMBL20416872 0.85 ADORA2A (0.49) ADORA2AADORA1ADORA2B
SCHEMBL20400722 0.85 ADORA2A (0.55) ADORA2AADORA1ADORA2B
SCHEMBL30401864 0.85 ADORA2A (0.55) ADORA2AADORA1ADORA2B
SCHEMBL20416965 0.83 ADORA2A (0.50) ADORA2AADORA1UCHL5ADORA2B
SCHEMBL30401332 0.83 ADORA2A (0.50) ADORA2AADORA1UCHL5ADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12195447-B2 Azolopyrimidine for the treatment of cancer-related disorders ARCUS BIOSCIENCES, INC. (US) 2025-01-14 — — US disclosed
EP-4310082-A2 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS Arcus Biosciences, Inc. (US) 2024-01-24 — — EP disclosed
EP-4310082-A2 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS Arcus Biosciences, Inc. (US) 2024-01-24 — — EP disclosed
EP-3570844-B1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES INC (US) 2023-09-06 — — EP disclosed
EP-3570844-B1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES INC (US) 2023-09-06 — — EP disclosed
US-20220144808-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. 2022-05-12 — — US disclosed
US-20220144808-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. 2022-05-12 — — US disclosed
US-11072597-B2 Azolopyrimidine for the treatment of cancer-related disorders ARCUS BIOSCIENCES, INC. 2021-07-27 — — US disclosed
US-11072597-B2 Azolopyrimidine for the treatment of cancer-related disorders ARCUS BIOSCIENCES, INC. 2021-07-27 — — US disclosed
US-20210101880-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. 2021-04-08 — — US disclosed
US-20210101880-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. 2021-04-08 — — US disclosed
US-10399962-B2 Azolopyrimidine for the treatment of cancer-related disorders ARCUS BIOSCIENCES, INC. (US) 2019-09-03 — — US disclosed
US-10399962-B2 Azolopyrimidine for the treatment of cancer-related disorders ARCUS BIOSCIENCES, INC. (US) 2019-09-03 — — US disclosed
US-20180215730-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. 2018-08-02 — — US disclosed
US-20180215730-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. 2018-08-02 — — US disclosed
US-20180215730-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. 2018-08-02 — — US disclosed
WO-2018136700-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. (US) 2018-07-26 — — WO disclosed
WO-2018136700-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. (US) 2018-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220144808-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885ADORA1 3/4885UCHL5 4138/4885
US-11072597-B2 Azolopyrimidine for the treatment of cancer-related disorders ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885ADORA1 3/4885UCHL5 4138/4885
US-12195447-B2 Azolopyrimidine for the treatment of cancer-related disorders ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885ADORA1 3/4885UCHL5 4138/4885
US-20180215730-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885ADORA1 3/4885UCHL5 4138/4885
US-10399962-B2 Azolopyrimidine for the treatment of cancer-related disorders ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885ADORA1 3/4885UCHL5 4138/4885
US-20210101880-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885ADORA1 3/4885UCHL5 4138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback